×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PVLA – palvella therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PVLA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/2
10:08 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/2
08:24 am
pvla
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Low
Report
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
2/2
07:30 am
pvla
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Medium
Report
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
1/29
08:03 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
1/16
12:28 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
1/12
06:12 am
pvla
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
Medium
Report
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
1/9
09:17 am
pvla
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]
Medium
Report
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]
1/9
07:30 am
pvla
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
Medium
Report
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
Date
Time
Symbol
Company Name
Action
%Chg
11/11/2025
07:30 am
PVLA
palvella therapeutics, inc.
MISS
Report
-4.6%
palvella therapeutics, inc.
8/14/2025
07:30 am
PVLA
palvella therapeutics, inc.
MISS
Report
3.9%
palvella therapeutics, inc.
5/15/2025
07:30 am
PVLA
palvella therapeutics, inc.
BEAT
Report
4.6%
palvella therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/9
04:09 pm
pvla
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Martini Jeffrey S
Medium
Report
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Martini Jeffrey S
2/9
04:08 pm
pvla
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Kline Ashley Hartmann
Medium
Report
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Kline Ashley Hartmann
2/9
04:07 pm
pvla
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Korenberg Matthew E
Medium
Report
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Korenberg Matthew E
2/9
04:07 pm
pvla
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Kaupinen Wes
Medium
Report
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Kaupinen Wes
2/9
04:05 pm
pvla
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Goin Kathleen
Medium
Report
Form 4 PALVELLA THERAPEUTICS, For: Feb 05 Filed by: Goin Kathleen
1/30
06:08 am
pvla
Form EFFECT PALVELLA THERAPEUTICS,
Medium
Report
Form EFFECT PALVELLA THERAPEUTICS,
1/29
04:09 pm
pvla
Form 8-K PALVELLA THERAPEUTICS, For: Jan 29
Medium
Report
Form 8-K PALVELLA THERAPEUTICS, For: Jan 29
1/23
04:05 pm
pvla
Form 4 PALVELLA THERAPEUTICS, For: Jan 21 Filed by: Goin Kathleen
Low
Report
Form 4 PALVELLA THERAPEUTICS, For: Jan 21 Filed by: Goin Kathleen
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: